Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 and SI-B003 in Extensive Stage Small Cell Lung Cancer
NCT05924841Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan, SI-B003 in small cell lung cancer (SCLC), sponsored by Biokin Pharmaceutical. Started Nov 2023; status: recruiting.
02
Drugs
izalontamab brengitecanSI-B003
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05924841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924841.